According to the latest unaudited financial results approved by the Board of Directors on August 7, 2026, iSERA Lifesciences reported a standalone net loss of ₹33.62 lakh for Q1FY27, marking a significant reversal from the ₹54.98 lakh profit recorded in Q4FY26. The company's financial performance showed a notable deterioration from the previous quarter, with zero revenue from operations and zero other income during the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by independent auditor G M K S & Co, Chartered Accountants, in accordance with Standard on Review Engagements (SRE 2410). The Board of Directors, including Managing Director Jayshree Suresh Jain, approved the results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company reported zero revenue from operations during Q1FY27, representing a complete absence of top-line growth compared to the ₹116.18 lakh revenue generated in Q4FY26. Additionally, other income also ceased, falling from ₹5.77 lakh in the previous quarter to zero in Q1FY27. This absence of revenue generation across both quarters indicates operational challenges or strategic restructuring initiatives that may be impacting the company's top-line performance. The company operates in the IT/ITES sector and has no separate reportable segments under Ind AS-108.
Despite the lack of revenue, iSERA Lifesciences incurred total expenses of ₹33.62 lakh during Q1FY27, resulting in a basic earnings per share (EPS) of ₹(1.60), compared to ₹1.58 in Q4FY26. The most critical aspect of the financial statement reveals a stark contrast between revenue generation and cost structure. Other expenses remained substantial at ₹31.31 lakh, accounting for nearly 93% of total quarterly outflows, suggesting that fixed or semi-fixed operational costs continue to be incurred despite the lack of business activity. This divergence between revenue and costs has led to the reserves deteriorating to ₹(49.81) lakh, a significant decline from ₹(16.19) lakh at the end of FY26. The paid-up equity share capital remains unchanged at ₹840.90 lakh.
According to latest market data, iSERA Lifesciences has demonstrated remarkable stock performance with 121 crore market capitalization and 3,278% growth over 1 year. The stock is currently trading at 143.90 with zero movement from the previous close of ₹143.90. The company's financial position shows promoter holding at 58.6%, though this has decreased by 41.4% over the last 3 years. The company's operational metrics include revenue of ₹1.36 crore and profit of ₹0.26 crore on a trailing twelve-month basis, indicating ongoing challenges despite the significant stock appreciation. As per the latest financial data, the company has maintained low operational costs with less than 1% of operating revenues towards interest expenses and 3.87% towards employee costs in the year ending March 31, 2026.
